BELIEF: Phase 2 trial of erlotinib and bevacizumab in non-small cell lung cancer - European Medical Journal

Continue

BELIEF: Phase 2 trial of erlotinib and bevacizumab in non-small cell lung cancer

Oncology
At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) phase 2 BELIEF clinical trial, which evaluated erlotinib and bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without the T790M mutation.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given